Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

NCT04546581 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

593

Enrollment

OTHER

Sponsor class

Conditions

COVID
COVID-19
SARS-CoV-2
SARS (Severe Acute Respiratory Syndrome)

Interventions

BIOLOGICAL: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
OTHER: Placebo
DRUG: Remdesivir

Sponsor

University of Minnesota

Collaborators

[object Object]
[object Object]
[object Object]